Meropenem

Indian Pediatrics

Volumn 42, Issue 5, 2005, Pages 443-450

  Shah, Dheeraj ^a,b   Narang, Manish ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b 7184 Birla Officers Flats ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM; CEFEPIME; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TAZOBACTAM;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INDIA; INFLAMMATION; MENINGITIS; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEWBORN INFECTION;

BACTERIAL INFECTIONS; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS; NEUTROPENIA; THIENAMYCINS;

EID: 19544379301     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Blumer JL. Meropenem: evaluation of a new generation carbapenem. Int J Antimicrob Agents 1997; 8:73-92.
2. Fish DN, Singletary TJ. Meropenem: A new carbapenem antibiotic. Pharmacotherapy 1997; 17:644-669.
3. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96:11-16.
4. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother 1995; 36: 35-41.
5. Hikida M, Kawashima K, Yoshida M, Mitsuhashi S. Inactivation of new carbapenem antibiotics by dehydropeptiase I from porcine and human renal cortex. J Antimicrob Chemother 1992; 30: 129-134.
6. Fukaswa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1b-methylsubstitution on its stability in the presence of renal dehydropeptidase I. Antimicob Agents Chemother 1992; 36: 1577-1579.
7. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1997; 28: 157-163.
8. Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC program in India. Int J Antimicrob Agents 2002; 20: 426-431.
9. Chang SC, Fang CT, Chen YC, Hsueh PR, Luh KT, Hsieh WC. In vitro activity of meropenem against common pathogenic bacteria isolated in Taiwan. Diagn Microbiol Infect Dis 1998; 32: 273-279.
10. Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001; 7:267-271.
11. Huizinga WKJ, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp-Korstanjep JA, et al. Antibiotic monotherapy with meropenem in the surgical management of intraabdominal infections. J Antimicrob Chemother 1995; 36: 179-189.
12. Hamacher J, Vogel F, Lichy J. Kohl FE, Diwok K, Wender H, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients - a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995; 36: 121-133.
13. Romaneilli G, Cravarezza, P, Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tract. J Antimicrob Chemother 1995; 36: 109-119.
14. Mouton YJ, Beuscart C, Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicob Chemother 1995; 36: 145-156.
15. Ayan M, Kuzucu C, Durmaz R, Aktas E, Cizmeci Z. Analysis of three outbreaks due to Klebsiella species in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24: 495-500.
16. Mahmood A, Karamat KA, Butt T. Neonatal sepsis: high antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit in Karachi. J Pak Med Assoc 2002; 52: 348-350.
17. Aktas E, Yigit N, Yazgi H, Ayyildiz A. Detection of antimicrobial resistance and extended-spectrum beta-lactamase production in Klebsiella pneumoniae strains from infected neonates. Int Med Res 2002; 30: 445-448.
18. Godula-Stuglik U, Mikusz G. Clinical efficacy of meropenem in the management of severe nosocomial infections in neonates. J Antimicrob Chemother 1999; 44: 63-64.
19. Beloborodova NV, Biryukov AV. Using meropenem ("Meronem" Zenca) in neonates. Clin Microbiol Infect 1997; 2: 124.
20. Koksal N, Hacimustafaoglu M, Bagci S, Celebi S. Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. Indian J Pediatr 2001; 68: 15-19.
21. Shah D, Narang M, Faridi MMA. Efficacy and safety of meropenem in neonatal sepsis. In: Abstracts: 42nd National Conference of the Indian Academy of Pediatrics; 2005 Jan 6-9; Kolkata, India. p.129.
22. Fleischhack G, Hartmann C, Simon A, Wulff B, Havers W, Marklein G, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47: 841-853.
23. Arrieta A. Use of meropenem in the treatment of serious infections in children: review of the current literature. Clin Infect Dis 1997; 24 (Suppl 2): S207-S212.
24. Hsu HL, Lu CY, Tseng HY, Lee PI, Lai HP, Lin WC, et al. Empirical monotherapy with meropenem in serious bacterial infections in children. Microbiol Immunol Infect 2001; 34: 275-280.
25. Hasegawa K, Chiba N, Kobayashi R, Murayama SY, Iwata S, Sunakawa K, et al. Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother 2004; 48: 1509-1514.
26. Sonntag J, Kaczmarek D, Brinkmann G, Kammler G, Hellwege HH. Complicating neonatal Escherichia coli meningitis. Z Geburtshilfe Neonatol 2004; 208: 32-35.
27. Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intra-ventricular polymyxin B: Case report and review. Clin Infect Dis 1999; 28: 1134-1138.
28. Paffetti A, D'Aviera L, Le Foche F, Mannozzi P, Mastropietro C, Croce GF. et al. Successful meropenem therapy of a brain abscess and meningitis arising from acute purulent otomastoiditis: Case report. Chemother 1998; 10: 132-135.
29. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000; 59: 653-680.
30. van Enk JG, Touw DJ, Lafeber HN. Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit 2001; 23: 198-201.
31. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand Infect Dis 1999; 31: 3-10.
32. Del Favero A. Clinically important aspects of carbapenem safety. Curr Opin Infect Dis 1994; 7: S38-S42.
33. Noorby SR, Faulkner KL, Newell PA. Differentiating meropenem and imipenem/ cilastatin. Infect Dis Clin Pract 1997; 6: 291-303.
34. Navaneeth BV, Sridaran D, Sahay D, Belwadi MR. A preliminary study on metallo-beta-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2002; 116: 264-267.